tiprankstipranks
Advertisement
Advertisement

ACAD Stock Latest News

Acadia Pharmaceuticals announces EC marketing authorization for Daybu
The FlyAcadia Pharmaceuticals announces EC marketing authorization for Daybu
24h ago
ACAD
Costco’s Healthcare Move Turns Heads. We’re Buying These Pharma Stocks Instead.
PremiumMarket News
Costco’s Healthcare Move Turns Heads. We’re Buying These Pharma Stocks Instead.
6d ago
JNJ
MRK
Acadia Pharmaceuticals price target raised to $49 from $45 at UBS
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $49 from $45 at UBS
8d ago
ACAD
Acadia Pharmaceuticals price target raised to $41 from $38 at Needham
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $41 from $38 at Needham
8d ago
ACAD
ACADIA Pharmaceuticals: Buy Rating Reiterated on Undervalued Growth Story; $36 Price Target Unchanged
PremiumRatings
ACADIA Pharmaceuticals: Buy Rating Reiterated on Undervalued Growth Story; $36 Price Target Unchanged
12d ago
ACAD
ACADIA Pharmaceuticals Earnings Call Signals Growth Momentum
PremiumCompany AnnouncementsACADIA Pharmaceuticals Earnings Call Signals Growth Momentum
13d ago
ACAD
Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley
Premium
The Fly
Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley
15d ago
ACAD
Acadia Pharmaceuticals price target raised to $39 from $35 at Citi
Premium
The Fly
Acadia Pharmaceuticals price target raised to $39 from $35 at Citi
15d ago
ACAD
ACADIA: Buy Rating Reiterated as Analyst Sees Favorable Risk-Reward Ahead of RADIANT Readout; $37 Price Target Unchanged
PremiumRatings
ACADIA: Buy Rating Reiterated as Analyst Sees Favorable Risk-Reward Ahead of RADIANT Readout; $37 Price Target Unchanged
20d ago
ACAD
Acadia Pharmaceuticals: Buy Rating Reiterated as Growth Drivers Strengthen; Price Target Maintained at $36
PremiumRatings
Acadia Pharmaceuticals: Buy Rating Reiterated as Growth Drivers Strengthen; Price Target Maintained at $36
20d ago
ACAD
Acadia Pharmaceuticals price target raised to $31 from $30 at BofA
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $31 from $30 at BofA
20d ago
ACAD
ACADIA: Hold Rating Reaffirmed as Strong Daybue Sales Drive FY26 Guidance Raise; $26 Price Target Maintained
PremiumRatings
ACADIA: Hold Rating Reaffirmed as Strong Daybue Sales Drive FY26 Guidance Raise; $26 Price Target Maintained
20d ago
ACAD
Acadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer
PremiumThe FlyAcadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer
20d ago
ACAD
Acadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital
Premium
The Fly
Acadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital
20d ago
ACAD
Acadia Pharmaceuticals price target raised to $36 from $35 at Mizuho
Premium
The Fly
Acadia Pharmaceuticals price target raised to $36 from $35 at Mizuho
20d ago
ACAD
Acadia Pharmaceuticals price target raised to $36 from $35 at Citizens
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $36 from $35 at Citizens
20d ago
ACAD
Acadia Pharmaceuticals: Buy Rating Reaffirmed on Strong Q2, Raised Revenue Guidance and Pipeline Catalysts; $38 Price Target Unchanged
PremiumRatings
Acadia Pharmaceuticals: Buy Rating Reaffirmed on Strong Q2, Raised Revenue Guidance and Pipeline Catalysts; $38 Price Target Unchanged
20d ago
ACAD
ACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating
PremiumRatings
ACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating
20d ago
ACAD
Acadia Pharmaceuticals reports Q2 EPS 18c, consensus 4c
PremiumThe Fly
Acadia Pharmaceuticals reports Q2 EPS 18c, consensus 4c
21d ago
ACAD
Acadia raises FY26 revenue view to $1.24B-$1.3B from $1.22B-$1.28B
PremiumThe FlyAcadia raises FY26 revenue view to $1.24B-$1.3B from $1.22B-$1.28B
21d ago
ACAD
ACADIA Pharmaceuticals Inc. (ACAD) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
ACADIA Pharmaceuticals Inc. (ACAD) Q2 Earnings Cheat Sheet
23d ago
ACAD
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
Premium
The Fly
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
1M ago
ACAD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >